James H. Stanker - Dec 31, 2022 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Chief Financial Officer
Signature
/s/ James H. Stanker by Michael B. Kirwan, as Attorney-in-Fact
Stock symbol
PCSA
Transactions as of
Dec 31, 2022
Transactions value $
$0
Form type
4
Date filed
1/4/2023, 04:42 PM
Previous filing
Oct 5, 2022
Next filing
Feb 10, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCSA Restricted Stock Units Award $0 -13K -3.54% $0.00 353K Dec 31, 2022 Common Stock 13K $0.00 Direct F1
transaction PCSA Restricted Stock Units Award $0 -69.7K -14.16% $0.00 422K Jan 1, 2023 Common Stock 69.7K $0.00 Direct F2
transaction PCSA Restricted Stock Units Award $0 -96.2K -15.64% $0.00 518K Jan 1, 2023 Common Stock 96.2K $0.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. These restricted stock units vest on date grant.
F2 Each restricted stock units represents a contingent right to receive one share of the lssuers common stock, following its vesting on 01/01/24, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death.
F3 Each restricted stock units represents a contingent right to receive one share of the Issuers common stock, following its vesting of one-third on 01/01/24; 01/01/25 and 01/01/26, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death.